Healthcare - Biotechnology - NASDAQ - US
$ 2.61
-6.79 %
$ 43.9 M
Market Cap
-0.61
P/E
INCOME STATEMENT
1.5 M
REVENUE
-25.1 M
OPERATING INCOME
-27.8 M
NET INCOME
EFFICIENCY
Earnings Waterfall
OncoCyte Corporation
| Revenue | 1.5 M |
| Cost Of Revenue | 1.09 M |
| Gross Profit | 413 K |
| Operating Expenses | 25.6 M |
| Operating Income | -25.1 M |
| Other Expenses | 2.64 M |
| Net Income | -27.8 M |
Income Statement
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | Dec-2016 | Dec-2015 | Dec-2014 | Dec-2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Revenue | 1.5 | 1.0 | 7.7 | 1.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GROSS PROFIT | |||||||||||
| Cost Of Revenue | 1.1 | 1.0 | 7.5 | 1.9 | 0.3 | 0.6 | 0.6 | 0.4 | 0.3 | 0 | 0 |
| Gross Profit | 0.4 | 18 K | 0.2 | (0.6) | (0.3) | (0.6) | (0.6) | (0.4) | (0.3) | 0 | 0 |
| OPERATING INCOME | |||||||||||
| Operating Expenses | 25.6 | 30.3 | 47.1 | 33.1 | 22.2 | 15.2 | 18.8 | 11.1 | 8.7 | 5.0 | 3.5 |
| Selling, General and Administrative Expenses | 13.5 | 23.0 | 33.5 | 23.3 | 15.4 | 8.7 | 11.7 | 5.5 | 4.2 | 1.0 | 0.6 |
| Research and Development Expenses | 9.3 | 7.3 | 13.6 | 9.8 | 6.8 | 6.5 | 7.2 | 5.7 | 4.5 | 4.0 | 2.9 |
| Operating Income | (25.1) | (18.0) | (46.9) | (29.7) | (22.2) | (15.2) | (18.8) | (11.1) | (8.7) | (5.0) | (3.5) |
| PRE-TAX INCOME | |||||||||||
| Interest Income Expense | 52 K | 77 K | 0.2 | 0.3 | 0.3 | 0.2 | 0.2 | 28 K | 19 K | 2 K | 0 |
| Total Other Income | 0.3 | (0.6) | 0.9 | (1.5) | (0.2) | (0.6) | (0.5) | 28 K | 17 K | 13 K | 0 |
| Pre-Tax Income | (24.9) | (18.6) | (73.4) | (31.2) | (22.4) | (15.8) | (19.4) | (11.2) | (8.7) | (5.0) | (3.5) |
| NET INCOME | |||||||||||
| Tax Provision | 0 | 54.8 | (9.3) | (1.3) | 97 K | (0.3) | 0.2 | (0.4) | (0.3) | 9 K | 0 |
| Net Income | (27.8) | (73.4) | (64.1) | (29.9) | (22.3) | (15.8) | (19.4) | (11.2) | (8.7) | (5.0) | (3.5) |
| EPS | 3.75 | 13.3 | 14.4 | 9.14 | 8.71 | 8.32 | 12.8 | 8.42 | 8.32 | 15.4 | 10.8 |